Vaccinex, Inc. (VCNX) stock
VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)
Close on Oct 19, 2026Market cap $3.22MP/E –Yield –
Vaccinex price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Vaccinex's price to sales ratio was 4.5× on Oct 19, 2026, against 2.8× a year earlier. Over the last 5 years it ranged from 2.2× to 161.1×, with a median of 13.8×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Oct 19, 2026 | 4.5× | −0.3 |
| 2025 | Dec 31, 2025 | 4.8× | −1.8 |
| 2024 | Dec 31, 2024 | 6.6× | +2.5 |
| 2023 | Dec 29, 2023 | 4.0× | −41.1 |
| 2022 | Apr 29, 2022 | 45.2× | +9.6 |
| 2021 | Dec 31, 2021 | 35.6× | −68.3 |
| 2020 | Apr 30, 2020 | 103.9× | +26.2 |
| 2019 | Dec 31, 2019 | 77.7× | – |
See a number that looks wrong?